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Objective: The Department of Hematology, Zealand University Hospital, Denmark, and the 
National Institute of Public Health, University of Southern Denmark, created the first nation-
wide, population-based, and the most comprehensive cross-sectional health-related quality of 
life (HRQoL) survey of patients with myeloproliferative neoplasms (MPNs). In Denmark, all 
MPN patients are treated in public hospitals and treatments received are free of charge for these 
patients. Therefore, MPN patients receive the best available treatment to the extent of its suit-
ability for them and if they wish to receive the treatment. The aims of this article are to describe 
the survey design and the characteristics of respondents and nonrespondents.
Material and methods: Individuals with MPN diagnoses registered in the Danish National 
Patient Register (NPR) were invited to participate. The registers of the Danish Civil Registra-
tion System and Statistics Denmark provided information regarding demographics. The survey 
contained 120 questions: validated patient-reported outcome (PRO) questionnaires and additional 
questions addressing lifestyle.
Results: A total of 4,704 individuals were registered with MPN diagnoses in the NPR of 
whom 4,236 were eligible for participation and 2,613 (62%) responded. Overall, the respon-
dents covered the broad spectrum of MPN patients, but patients 70–79 years old, living with 
someone, of a Danish/Western ethnicity, and with a higher level of education exhibited the 
highest response rate.
Conclusion: A nationwide, population-based, and comprehensive HRQoL survey of MPN 
patients in Denmark was undertaken (MPNhealthSurvey). We believe that the respondents 
broadly represent the MPN population in Denmark. However, the differences between respon-
dents and nonrespondents have to be taken into consideration when examining PROs from the 
respondents. The results of the investigation of the respondents’ HRQoL in this survey will 
follow in future articles.
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Introduction
The chronic myeloproliferative neoplasms (MPNs) encom-
pass two disease groups: 1) chronic myeloid leukemia (CML) 
with the Philadelphia chromosome and 2) the main diseases 
essential thrombocythemia (ET), polycythemia vera (PV), and 
myelofibrosis (MF) without the Philadelphia chromosome.1 
The diseases are caused by acquired damage to hematopoetic 
stem cells.1 The nature of MPNs is a chronic disease course, 
but mean lifespan is decreased, which is most pronounced in 
MF patients.2,3 Philadelphia-negative MPNs may change from 
an early cancer stage (ET and PV) to an advanced cancer stage 
(MF) with intervening transitional stages.4,5 CML may turn 
into blast crisis.6 Philadelphia-negative MPNs may also turn 
into blast crisis/acute myeloid leukemia (AML).1 For MPN 
patients who develop blast crisis/AML, the mean survival is 
only a few months.7,8 Previously, the management of these 
diseases aimed to relieve symptoms and to reduce the risk of 
thrombotic complications.8 Allogeneic stem cell transplanta-
tion is potentially curative, but unfortunately this treatment 
possibility only exists for a minority of patients.8,9 However, 
due to increased knowledge of specific genetic defects and 
molecular properties, a new targeted medical treatment era 
has evolved. Because of targeted treatment, overall survival 
of CML patients is prolonged significantly and, hopefully, 
the lifespan approaches that of the general population.10,11 
Targeted treatment for ET, PV, and MF patients is expected 
to prolong overall survival.12–16
Previous studies have investigated health-related quality 
of life (HRQoL) in MPN patients.17–41 The presentation of 
symptoms depends on the MPN subtype, and the symptom 
profiles vary greatly from asymptomatic to burdensome.17–41 
Given the knowledge of burdensome symptom profiles and 
impaired HRQoL in many MPN patients, a comprehensive 
patient-reported outcome (PRO) survey of a large, repre-
sentative MPN population is warranted. A more extensive 
understanding of the patients’ health conditions and the 
influences on quality of life is likely to improve both medical 
treatments and thus prevent disease progression and wors-
ening of symptoms, rehabilitation, and care. Given that 
CML patients have an overall longer lifespan that possibly 
approaches the lifespan of the general population in the new 
targeted treatment era,3 it is relevant to investigate whether 
the HRQoL of these patients correspondingly approach those 
of the general population.
In Denmark, all MPN patients are treated in public 
hospitals. The diagnoses of all patients are obtained in the 
hospital, and diagnosis codes are recorded in the National 
Patient Register (NPR).42,43 As the treatment is free of charge 
for MPN patients, majority of these patients receive the 
best available treatment. The best available treatment may 
not be suitable for a minority of MPN patients and there 
may be some MPN patients who do not wish to receive the 
best available treatment. We decided to undertake the first 
nationwide, population-based, and the most comprehensive 
HRQoL survey of MPN patients, who receive the best avail-
able treatment to the extent of its suitability for the patients 
and if they wish to receive the treatment. The PROs will 
be adjusted for potential confounding variables based on 
information from national registers.42–45
Objective
The purpose of this article is to present the survey design 
and the results of an examination of whether the respondents 
are representative of the entire MPN population in Denmark 
prior to analyzing PROs from the respondents. The results 
of the PRO examination will follow in future articles. Fur-
thermore, this article with description of the survey design 
and characteristics of the respondents and nonrespondents 
to the survey will serve as a reference for future research 
articles because the MPN population and the PROs from the 
MPNhealthSurvey will serve as mainstays for future research.
Material and methods
Participants
The inclusion criteria were the following: 1) An MPN diagnosis 
of ET, PV, MF, unclassified MPN, or CML according to inter-
national diagnostic criteria9,11 registered in the NPR43 between 
1977 (the year of creation) and March 31, 2013. The diagnosis 
codes in the NPR are based on the International Classification of 
Diseases (ICD). ICD-8 was used from 1977 to 1993, and ICD-
10 was used from 1994 to 2013 (Table 1).  Some ICD-10 MPN 
diagnosis codes changed between 1994 and 2013. A patient’s 
MPN diagnosis may change due to disease progression,4,5 and a 
change in diagnosis is reported to the NPR. Therefore, if more 
than one diagnosis of MPN was registered for a patient, the last 
registered diagnosis was used. Denmark has a Cancer Register. 
All patients with diagnoses of cancer must be registered in the 
NPR, and all of these registrations are automatically passed on 
to the Cancer Register. We decided to use the NPR to identify 
the MPN patients for this survey. 2) The MPN diagnosis had to 
have been registered at least once at a department of hematology 
or at a department of internal medicine that treats or previously 
treated MPN patients in Denmark. Today, MPN patients are 
almost exclusively treated in departments of hematology. 3) 
The patient had to be 16 years or older on September 4, 2013. 
4) The patient had to be alive on September 4, 2013.
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Data collection
The names and personal identification numbers of all indi-
viduals in Denmark with MPN diagnoses were extracted from 
the NPR on September 4, 2013. All postal addresses were 
obtained from the Civil Registration System (CRS).42,44,45 
The patients who were alive, fulfilled all of the inclusion 
criteria, and who were not protected from inquiries during 
scientific surveys received a postal letter that was mailed on 
September 11, 2013. The mailing contained an introduction 
letter, a survey booklet, a prepaid stamped envelope, and 
a unique username for online login. The letter invited the 
patients to participate in the survey, described the survey’s 
purpose and content, and emphasized that participation was 
voluntary. A mixed-mode approach was used to collect the 
data. The respondents either could complete the enclosed 
survey booklet and return it in the enclosed envelope or 
answer the questions online. A reminder was sent to everyone 
who had not responded on October 25, 2013. The survey 
ended on December 31, 2013. The patients were not offered 
compensation for participation.
Questionnaires and additional questions
The survey booklet/website had 120 questions. The follow-
ing six validated questionnaires were used in the survey: 1) 
Short Form 36 Health Survey (SF-36) version 2.0,46 2) Brief 
Fatigue Inventory (BFI),47 3) Multidimensional Fatigue 
Inventory 20 (MFI-20),48 4) Hospital Anxiety and Depression 
Scale (HADS),49 5) European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30 
(EORTC QLQ-C30) version 3.0,50 and 6) Myeloprolifera-
tive Neoplasm Symptom Assessment Form (MPN-SAF).18 
For all questionnaires, the required  permissions for use in 
the MPNhealthSurvey were obtained. The questionnaires 
were available in Danish and validated, with exception of the 
MPN-SAF questionnaire. The MPN-SAF questionnaire was 
available in English and validated. This questionnaire was 
translated into Danish according to guidelines arranged by 
the research group prior to this survey.51
SF-36 is a generic questionnaire that investigates physi-
cal and mental health in addition to physical, mental, and 
social functioning.46 The questionnaire has 36 items that can 
be combined into eight scales and two summary measures: 
physical functioning, role-physical, bodily pain, general 
health, vitality, social functioning, role-emotional, mental 
health, a physical component summary measure, and a mental 
component summary measure. Role-physical measures limi-
tations due to physical health and role-emotional measures 
limitations due to emotional health, including limitations in 
daily work or other daily activities and limitations in pursuing 
hobbies or other leisure activities. The physical component 
summary measure and the mental component summary mea-
sure are derived and scored using a component analysis and 
takes into account all of the physical or mental components 
in the questionnaire. The scores and summary measures range 
from 0 to 100. Higher scores or summary measures indicate 
the more favorable conditions.
BFI and MFI-20 are symptom-specific fatigue question-
naires.47,48 BFI has nine items that cover the severity of fatigue 
and the impact on daily functioning. A score for each item 
can range from 0 to 10. Higher scores indicate more fatigue. 
A global fatigue score is found by averaging the scores of all 
items in the questionnaire. MFI-20 has 20 items and the fol-
lowing five scales: general fatigue, physical fatigue, reduced 
activity, reduced motivation, and mental fatigue. A score can 
range from 4 to 20. Higher scores indicate more fatigue.
HADS is a symptom-specific questionnaire that investi-
gates anxiety and depression.49 HADS has 14 items and two 
scales: anxiety and depression. A score can range from 0 to 
21. A score <8 is assessed as no anxiety/depression, a score 
of 8–10 is assessed as mild anxiety/depression, a score of 
11–14 is assessed as moderate anxiety/depression, and a score 
of 15–21 is assessed as severe anxiety/depression.
EORTC QLQ C-30 is a cancer disease-specific question-
naire that investigates HRQoL.50 The questionnaire has 30 
items that can be combined into five functional scales, three 
symptom scales, six single items, and global health status/
QoL. The functional scales cover physical, role, emotional, 
social, and cognitive functioning. The symptom scales cover 
fatigue, pain, and nausea/vomiting. The single items assess 
dyspnea, insomnia, appetite loss, constipation, diarrhea, and 
Table 1 The survey population was formed from the following 
diagnoses
ICD-8 codes Diagnoses
208.99 Polycythemia vera
287.29 Essential thrombocythemia
209 Myelofibrosis
205.19 Chronic myeloid leukemia
ICD-10 codes Diagnoses
D45 Polycythemia vera
D47.3 Essential thrombocythemia
D75.2 Essential thrombocythemia
D47.4 Osteomyelofibrosis
C94.4 Osteomyelofibrosis acuta
C94.5 Osteomyelofibrosis acuta
C92.1 Chronic myeloid leukemia
D47.1 Chronic myeloproliferative disease
Abbreviation: ICD, international classification of diseases.
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financial difficulties. The scores can range from 0 to 100. 
Higher scores on functional scales represent a great/healthy 
level of functioning. Higher scores on symptom scales 
 represent high level of symptomatology. A high score on the 
global health/QoL represents a high HRQoL. Danish popu-
lation-based reference data for EORTC QLQ C-30 will be 
used in future investigation of potential differences in HRQoL 
between the MPN subgroups and the general population.52
The MPN-SAF is a disease-specif ic questionnaire 
that specifically investigates the symptoms and QoL in 
MPN patients.18 MPN-SAF is co-administered with BFI. 
MPN-SAF co-administered with BFI includes a total of 26 
symptom items and one QoL item. The items are measured 
on 0–10 rating scale. High numbers indicate higher level of 
symptomatology or QoL impairment. The MPN-SAF Total 
Symptom Score (MPN-SAF TSS), which is an abbreviated 
symptom score developed from MPN-SAF and BFI, was 
also used in the survey.19 MPN-SAF TSS has 10 items, and 
the score ranges from 0 to 100.
A total of 25 items in the questionnaire booklet/on the 
website covered lifestyle, including physical activity, smok-
ing, and alcohol consumption, in addition to height, weight, 
social life, regularity in the intake of medication prescribed 
by a doctor, and if someone helped the respondent to com-
plete the questionnaire booklet or to answer the questions 
on the website. Furthermore, the respondents were able to 
write in free text.
Comorbidity and lifestyle
Comorbidity and lifestyle will be taken into account in 
future investigation of HRQoL in the MPN population. We 
will investigate, if there are differences in comorbidity and 
lifestyle between ET, PV, and MF participants and differences 
in lifestyle between the MPN population and the general 
population. Furthermore, in future research, PROs will be 
adjusted for comorbidity and lifestyle as confounders.
The Charlson Comorbidity Index (CCI) was used to 
assess the comorbidity burden. The CCI is a weighted index 
that consists of disease clusters that include chronic diseases 
and cancers.53,54 Information on comorbidities was obtained 
from the NPR, all diagnosis codes that were recorded between 
September 4, 2013, and the preceding 5 years were included.43 
MPNs were excluded from the CCI because the CCI will be 
used to adjust for the comorbidity confounders during the 
future investigation of the differences between patients with 
different MPN subtypes in PROs that were related to MPNs. 
The CCI scores were grouped into three categories: 1) no or 
low comorbidity (score of 0), 2) moderate comorbidity (score 
of 1–2), and 3) severe comorbidity (score of 3 or higher).
The participants in the MPNhealthSurvey were asked 
questions on height, weight, and lifestyle. BMI was divided 
into four categories: 1) <18.5, 2) 18.5–24.9, 3) 25.0–29.9, 
and 4) ≥30.0. Smoking status was divided into three catego-
ries: 1) smoker, 2) ex-smoker, and 3) non-smoker. Alcohol 
consumption was divided into four categories: 1) ≤7, 2) 8–14, 
3) 15–21, and 4) ≥22 units per week. Physical activity in lei-
sure time was divided into four categories: 1) hard training 
and competitive sports several times per week; 2) training, 
heavy garden work, or similar ≥4 hours per week; 3) walking, 
bicycling, light garden work, or similar ≥4 hours per week; 
and 4) reading, watching TV, or other sedentary activities.
Every few years, the National Institute of Public Health 
conducts a health and morbidity survey of the general popula-
tion of Denmark. The lifestyle data from the 2013 survey of 
the general population will serve as reference data in future 
investigation of potential differences in lifestyle between the 
MPN subgroups and the general population.55
Characteristics of the respondents and 
nonrespondents
The CRS provided information regarding the age, sex, and 
ethnicity (Danish/Western or non-Western).42,44,45 Statistics 
Denmark’s registers provided information about living 
arrangement (living alone or living with someone), education 
(basic school, upper secondary or vocational school, or higher 
education), and employment (employed or not employed).56 
The distributions of respondents and nonrespondents on MPN 
subtypes were calculated. The disease duration on September 
4, 2013 was established using the registration date for the 
first MPN diagnosis in the NPR.
Response rate, effect of the reminder, 
and response mode
The total response rate was calculated based on the respon-
dents who answered at least some items either initially or after 
receiving a reminder. The numbers of patients who initially 
responded and who responded after receiving a reminder were 
calculated. Both patients who did not respond to the request 
to participate in the survey and the patients who returned a 
survey booklet without answering any of the questions were 
registered as nonrespondents. The reasons for nonresponse 
were given spontaneously by some of the nonrespondents 
who either initiated a telephone call or returned the question 
booklet without any answers but provided a note explaining 
the reason for the nonresponse. Finally, the distributions 
of respondents who returned the survey booklet and who 
answered the questions online were determined.
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Associations between nonresponse and 
demographic factors
The demographic factors that were considered for potential 
influence on the nonresponse were age, sex, living arrange-
ment, education, employment, ethnicity, MPN subtype, and 
duration of disease.
Statistical analysis
Descriptive statistics were used to present the characteristics 
of respondents and nonrespondents and the online and paper 
submitters. Chi square tests were used to test for significant 
differences in contingency tables for demographic factors, 
and two sided Student’s t-tests were used to test for signifi-
cant differences in mean age between the groups. Logistic 
regressions were used to investigate the possible effects 
of the interactions between age and all other demographic 
characteristics, between sex and all other demographic 
characteristics and between MPN subtype and all other 
demographic characteristics on nonresponse. A significance 
level of 0.05 was used. SAS version 9.3 was used for all 
statistical analyses.
Ethics
The Danish Data Protection Agency approved the survey 
(SJ-RO-02). In Denmark, register studies and questionnaire 
studies are exempted from requirement of approval from 
the Committee on Health Research Ethics (Committee Act 
section 14, 2).57 Future research using the MPN population 
and the PRO mainstay from the MPN population may require 
approval from the Committee on Health Research Ethics, 
which will then be requisitioned.
During the survey, the recipients of the invitation to partici-
pate in the survey had the opportunity to contact the research 
group by phone and by email. Thus, it was possible for them to 
ask clarifying questions both regarding the invitation to partici-
pate in the survey and the survey questions. Completion of survey 
was deemed to be agreement of consent from the participants.
Results
Participants
A total of 4,704 individuals registered with MPN diagnoses 
between 1977 and March 31, 2013, were alive, and fulfilled 
all of the inclusion criteria (Figure 1). Of these  individuals, 
Figure 1 Flowchart of the survey population.
Abbreviation: MPN, myeloproliferative neoplasm.
Individuals with an MPN diagnosis 
in the National Patient Register,
n=4,704
Individuals invited to participate,
n=4,296
Protected from inquiry, n=408 (9%)  
Individuals who were sent and
presumably received an invitation
letter, n=4,285   
Not found on the address, n=11 (0.3%)
Individuals with an MPN diagnosis 
in the National Patient Register 
eligible for participation, 
n=4,236 (100%)
Dead, n=8 (0.2%)
Mistakenly registered in the
National Patient Register
having an MPN diagnosis, n=41 (1%)
Nonrespondents, n=1,623 (38%)
Nonrespondents who gave a reason
for refusal of participation, n=23 (1%)
Respondents (participants), n=2,613 (62%)
Responded initially, n=1,955 (46%)
Responded after reminder, n=658 (16%)
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408 were protected from inquiry by scientific surveys. 
Therefore, 4,296 individuals were invited to participate in 
the survey. Eleven individuals were not found at the postal 
addresses registered in the CRS. Thus, presumably 4,285 
individuals received an invitation letter. We were informed 
by relatives that eight individuals had died in the days lead-
ing up to receipt of the  invitation to participate in the survey. 
Finally, 41 individuals replied that they did not know about 
having an MPN diagnosis and that they had never consulted a 
hematologist or a doctor at a medical department at a hospital 
for diagnostic investigation. Thus, 4,236 individuals with 
an MPN diagnosis in the Danish National Patient Register 
formed the survey population.
Characteristics of the respondents and 
nonrespondents
The mean age of the nonrespondents was slightly higher than 
the mean age of the respondents (respondents: age 67.9 years 
and nonrespondents: age 69.4 years; Table 2). The response rate 
was slightly higher for males than females, but the difference 
was not significant (males: 62% and females: 61%). The highest 
response rate was that of patients aged 70–79 years (females: 
67% and males: 68%). The response rate was remarkably higher 
among those living with someone compared with those living 
alone (living with someone: 69% and living alone: 51%). The 
patients with higher education exhibited a higher response rate 
than the patients who had attended upper secondary/vocational 
school or basic school (higher education: 71%, upper second-
ary/vocational school: 67%, and basic school: 52%). The 
patients who were Danish or living in Denmark but were born 
in another Western country exhibited a higher response rate 
than patients who were living in Denmark but were born in a 
non-Western country (Danish/Western: 63% and non-Western: 
44%). The MF patients exhibited the highest response rate com-
pared to the other MPN subgroups (MF: 69%, ET: 60%, PV: 
60%, and CML: 66%). The patients who were diagnosed with 
MPN <1 year before the survey exhibited a higher response rate 
than those who were diagnosed with MPN≥1 year before the 
survey, but this difference was not significant (<1 year: 67%, 
1–4 years: 63%, and ≥5 years: 61%). Furthermore, the CML 
respondents had a stronger preference for answering the ques-
tions online than the other MPN subgroups, but the difference 
was not significant (CML online: 24%).
Response rate, effects of the reminder, 
and response mode
A total of 2,613 (62%) patients responded, including 1,955 
(46%) who initially responded and 658 (16%) who responded 
after receiving a reminder (Figure 1). Of the participants, 
2,153 (82%) completed the survey booklet, and 460 (18%) 
answered the questions online (Table 2).
Associations between nonresponse and 
demographic factors
An interaction was found between nonresponse, age, and 
education (p<0.0001), but this was primarily due to the retired 
participants for whom the amount of missing information 
regarding education was significant. There were no other inter-
actions between the nonresponses and the demographic factors.
Discussion
A nationwide HRQoL survey of MPN patients (MPNhealth-
Survey) was undertaken. In total, 2,613 (62%) patients 
responded. We believe that the respondents overall covered 
the broad spectrum of MPN patients, but the highest response 
rate was that of patients 70–79 years old, living with some-
one, of a Danish/Western ethnicity, and with a higher level 
of education. The number of MF participants was only 88. 
The differences in age, sex, living arrangement, ethnicity, and 
educational level between respondents and nonrespondents in 
the Danish National Health Survey performed on the general 
population in 2010 have been examined, and the pattern of 
differences is the same as in the MPNhealthSurvey.55
The MPNhealthSurvey has strengths. This was the first 
nationwide, population-based HRQoL survey of MPN 
patients, who receive the best available treatment to the 
extent of its suitability for the patients and if they wish to 
receive the treatment.17–41 The selection bias was minimized 
because all MPN patients living in Denmark and registered 
in the NPR were invited to participate. The mixed-mode 
approach to data collection ensured that access to and ability 
to navigate the Internet was not a condition of participating. 
To the best of our knowledge, this MPN population is the 
largest ever that submitted PROs.17–41 However, the CML 
population was larger in, for example, a study by Efficace et 
al.32,36 Overall, we believe the respondents are representative 
of the MPN patients in Denmark. However, the differences in 
characteristics between the respondents and nonrespondents 
and the relatively small number of MF participants must be 
taken into consideration when examining the PROs from 
the respondents. Furthermore, there may be differences in 
characteristics between respondents and nonrespondents, 
which we were not aware of. The HRQoL investigation is 
comprehensive and has not previously been reported on a 
MPN population to a similar extent.17–41 The differences in 
PROs between the MPN subgroups were adjusted for age, 
sex, comorbidity, and lifestyle. The  adjustment for confound-
ers was appropriate because we wished to examine HRQoL 
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Table 2 Differences between respondents and nonrespondents and differences between online and paper submitters in demographics, 
MPN subtype, and duration of disease
Demographic and disease 
characteristic
Respondents Nonrespondents p-Value for 
difference
Online Paper p-Value for 
difference
Total, n (%) 2613 (62) 1623 (38) 460 (18) 2153 (82)
Age, mean ± SD, median 67.9±12.9, 69.6 69.4±15.0, 70.9 0.004 60.5±12.1, 62.3 69.5±12.48, 70.9 <0.0001
Sex, n (%)
Female 1435 (61) 915 (39) >0.1* 202 (14) 1233 (86) <0.0001*
Male 1178 (62) 708 (38) 258 (22) 920 (78)
Female, years, n (%)
20–29 9 (56) 7 (44) <0.0001 4 (44) 5 (56) <0.0001
30–39 29 (54) 25 (46) 8 (28) 21 (72)
40–49 98 (59) 69 (41) 22 (22) 76 (78)
50–59 208 (66) 107 (34) 49 (24) 159 (76)
60–69 375 (67) 181 (33) 76 (20) 299 (80)
70–79 436 (67) 211 (33) 37 (8) 399 (92)
80–89 247 (51) 234 (49) 5 (2) 242 (98)
≥90 33 (29) 81 (71) 1 (3) 32 (97)
Male, years, n (%)
20–29 7 (54) 6 (46) 0.003 3 (43) 4 (57) <0.0001
30–39 29 (57) 22 (43) 13 (45) 16 (55)
40–49 85 (56) 67 (44) 37 (44) 48 (56)
50–59 179 (61) 115 (39) 61 (34) 118 (66)
60–69 331 (64) 185 (36) 87 (26) 244 (74)
70–79 373 (68) 177 (32) 53 (14) 320 (86)
80–89 158 (59) 112 (41) 3 (2) 155 (98)
≥90 16 (40) 24 (60) 1 (6) 15 (94)
Living arrangement, n (%)
Living alone 834 (51) 787 (49) <0.0001** 88 (11) 746 (89) <0.0001**
Living with someone 1758 (69) 786 (31) 370 (21) 1388 (79)
Missing, n 21 50 2 19 
Education, n (%)
Basic school 768 (52) 698 (48) <0.0001** 64 (8) 704 (92) <0.0001**
Upper secondary/vocational 
school
1199 (67) 591 (33) 234 (20) 965 (80)
Higher education 589 (71) 246 (29) 154 (26) 435 (74)
Missing, n 57 88 8 49
Employment, n (%)
Employed 782 (66) 396 (24) 0.0006** 243 (31) 539 (69) <0.0001**
Unemployed 62 (56) 49 (44) 20 (32) 42 (68)
Retired 1768 (60) 1178 (40) 197 (11) 1571 (89)
Missing, n 1 0 0 1
Ethnicity, n (%)
Danish/Western 2481 (63) 1432 (37) <0.0001** 442 (18) 2039 (82) 0.1**
Non-Western 111 (44) 141 (56) 16 (14) 95 (86)
Missing, n 21 50 2 19 
MPN subtype, n (%)
ET 816 (60) 549 (40) 0.02** 164 (20) 751 (80) >0.1**
PV 915 (60) 606 (40) 143 (16) 673 (74)
MF 88 (69) 39 (31) 12 (14) 76 (86)
CML 362 (66) 185 (44) 88 (24) 274 (76)
MPN unclassified 432 (64) 244 (36) 53 (12) 379 (88)
Duration of disease, years, n (%)
<1 176 (67) 86 (33) 0.06** 33 (19) 143 (81) >0.1**
1–4 909 (63) 544 (37) 172 (19) 737 (81)
≥5 1528 (61) 993 (39) 255 (17) 1273 (83)
Notes: *Adjusted for age. **Adjusted for age and sex.
Abbreviations: CML, chronic myeloid leukemia; ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; PV, polycythemia vera.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
17
8.
2 
on
 1
6-
Ap
r-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
148
Brochmann et al
related to MPN. The CRS register provided data on age and 
sex, and the NPR provided data on comorbidity. The registers 
ensured a high validity in the adjustment for the confounders’ 
age, sex, and comorbidity.
The MPNhealthSurvey has limitations. The NPR is gen-
erally considered to be valid, including for hematological 
malignancies. However, registries are not entirely complete. 
Because reporting disease diagnoses to the NPR in Denmark 
is an enforced requirement and is performed systematically, 
incorrect registrations can only marginally have influenced 
the results. Individuals who got surprised and frightened when 
they received an invitation to participate in the survey because 
they did not know about having an MPN diagnosis registered 
in the NPR, could contact the research group performing the 
survey by phone and email. The individuals who turned out 
not having a connection to a department of hematology or 
to a department of internal medicine because of MPN, but 
were registered in the NPR, were recommended to contact 
their general practitioner to clarify, if the registration in the 
NPR was a mistake. The large number of questions in the 
survey may have prevented some patients from participating. 
The symptomatic patients may have been more motivated to 
participate than the asymptomatic patients, and the patients 
with very severe symptom burdens may not have been able 
to participate, and this may have influenced the PROs. Some 
MPN patients’ disease coping strategy may include not think-
ing about the potential long-term effects of the disease. These 
patients may be nonrespondents in this survey. The survey 
was based on an anonymous self-report and, for example, 
unhealthy lifestyles may have been underreported. The survey 
was based on written questions. Therefore, dyslexic patients, 
patients with visual impairments, and patients who were not 
familiar with the Danish language may not have been able 
to participate or may have had difficulties participating. The 
questionnaire MPN-SAF has been validated in English. The 
questionnaire was translated into Danish according to guide-
lines for translation of questionnaires prior to this survey. 
However, it has not been fully validated in Danish. It would 
have been appropriate to fully validate the MPN-SAF in 
Danish by completing cognitive interviews and thus letting 
MPN patients validate the translation. Cognitive debriefing of 
MPN-SAF could potentially have led to appropriate linguistic 
changes in the questionnaire.51
The reason for not sending an invitation to participate 
in the survey to patients diagnosed with MPN within half a 
year prior to the start of the survey was that we believed that 
newly diagnosed patients could potentially be in psychologi-
cal crisis because of the recent diagnosis of incurable cancer.
The MPN patients received a reminder, if they had not 
responded by October 25, 2013. More reminders could have 
raised the response rate, but because the target population 
was patients with chronic cancer, more than one reminder 
could not be justified.
PROs from the MPN patients who developed AML before 
this survey was performed, and those who underwent bone 
marrow transplantation before this survey was performed 
will be separately analyzed.
Conclusion
A nationwide HRQoL survey of MPN patients in Denmark 
termed MPNhealthSurvey was performed. We believe that 
the respondents broadly represent the MPN population in 
Denmark. However, the differences between respondents 
and nonrespondents have to be taken into consideration when 
examining PROs from the respondents. The participants pro-
vided disease-specific and generic PROs for investigation. 
The MPNhealthSurvey is the first nationwide and population-
based survey, has the largest MPN population, and presents 
the most extensive PRO collection from a MPN population 
receiving best available treatment to date. The results of the 
PRO survey will follow in future articles. The PROs and the 
MPN population will serve as mainstays for future research. 
Future research will link to the Danish registries to investigate 
factors, such as 1) the ability to stay employed, 2) the extent 
of health service utilization, and 3) mortality.
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